RESEARCH PLAN ? RUTGERS CANCER INSTITUTE OF NEW JERSEY OVERALL PROJECT SUMMARY/ABSTRACT The Rutgers Cancer Institute of New Jersey (CINJ) is a matrix/consortium (with Princeton University) and New Jersey?s only NCI-designated Comprehensive Cancer Center, serving a diverse population of 8.9 million people. CINJ focused the strengths and resources of the major research institutions in NJ on addressing the cancer burden in its catchment area (NJ). The rapid trajectory of CINJ?s growth validated the initial vision that one of the Nation?s largest public universities of the health sciences would rapidly bring forth an NCI-designated Cancer Center. CINJ has 227 members (206 Rutgers, 19 Princeton, and 2 collaborating). The State Cancer Registry and Surveillance, Epidemiology, and End Results (SEER) Program was moved to CINJ in 2011, and as a result of state legislation in 2013, CINJ became an independent institute of Rutgers University, optimizing CINJ?s potential for growth, transdisciplinary collaboration, and impact across the catchment area. In FY2018, CINJ received over $68 million in support from Rutgers and Princeton, the State, the Health System, and philanthropy. Direct peer-reviewed support increased ~16%. Members published 3,664 cancer focused publications since 2011 (20% inter- and 24% intra-programmatic, 55% inter-institutional). In January 2017, Steven K. Libutti was appointed Director of CINJ and Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences (RBHS). In a strategic partnership with the RWJBarnabas Health System, Libutti was named Senior Vice President for Oncology Services. CINJ is now positioned to coordinate both cancer research and care throughout its catchment area. An iterative strategic planning process resulted in reorganization of research Programs to increase collaborations, cancer focus, translation, and investigator-initiated clinical trials. These five Programs are: 1) Cancer Metabolism and Growth (CMG), 2) Genomic Instability and Cancer Genetics (GICG), 3) Cancer Pharmacology (CP), 4) Clinical Investigations and Precision Therapeutics (CIPT), and 5) Cancer Prevention and Control (CPC). These Programs are supported by eight shared resources (Biomedical Informatics, Biometrics, Biorepository and Histopathology Services, Comprehensive Genomics, Flow Cytometry/Cell Sorting, Genome Editing, Metabolomics, and Research Pharmacy), with two developing shared resources (Immune Monitoring, Small Molecule Screening). The Statewide authority of CINJ derives from its status as the only NCI-designated Cancer Center; extensive and direct support by the State of New Jersey to serve as the State?s oncology resource; opportunities to conduct translational and population research within the most diverse and densely populated State in the nation; and the synergistic opportunities for collaboration across outstanding research institutions. This supports CINJ?s mission to reduce the burden of cancer in its catchment by advancing cancer research, prevention, screening and education.

Public Health Relevance

RUTGERS CANCER INSTITUTE OF NEW JERSEY PUBLIC HEALTH RELEVANCE STATEMENT New Jersey has a population of approximately 8.9 million with a yearly cancer incidence of 50,000 new cases and a yearly mortality of 16,500 deaths. Rutgers Cancer Institute of New Jersey (CINJ) is the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center. The mission of CINJ is to reduce the burden of cancer by advancing cancer research, prevention, screening and education for one of the nation?s most diverse and densely populated states as well as for the broader nation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rbhs -Cancer Institute of New Jersey
Overall Medical
New Brunswick
United States
Zip Code
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Llanos, Adana A M; Tsui, Jennifer; Rotter, David et al. (2018) Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health 18:162
Hadigol, Mohammad; Khiabanian, Hossein (2018) MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications. BMC Bioinformatics 19:219
Severson, Eric A; Riedlinger, Gregory M; Connelly, Caitlin F et al. (2018) Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:2501-2505
Shih, Weichung Joe; Lin, Yong (2018) Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 37:687-709
Ding, Qiang; Gaska, Jenna M; Douam, Florian et al. (2018) Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc Natl Acad Sci U S A 115:E6310-E6318
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357

Showing the most recent 10 out of 775 publications